China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited (CSWYF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cswyf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for China Shineway Pharmaceutical Group Limited (CSWYF) measures how much investors pay for each dollar of the company's trailing earnings. CSWYF's current PE ratio of 5.72x is calculated by dividing its stock price of $1.08 by its TTM earnings per share of $1.26. −10.8% discount vs 5Y avg 6.4x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2015 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 11 fiscal years · Front-end computedMinQ1 · 25%9.3x
MedianQ3 · 75%21.9x
Max
At 5.72x, CSWYF's current P/E is lower than in 18% of its annual fiscal year readings over the past 11 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
China Shineway Pharmaceutical Group LimitedYou CSWYF | $816M | 5.72x | -85.7% | $1.26 |
 Adcock Ingram Holdings Limited AIHLF | $624M | 7.40x | -81.5% | $5.85 |
 Columbia Care Inc. CCHWF | $521M | N/A | — | -$0.26 |
 EBR Systems, Inc. EBRCZ | $262M | N/A | — | -$0.12 |
 Inventiva S.A. IVEVF | $556M | N/A | — | -$1.90 |
 Kindstar Globalgene Technology, Inc. KDGTF | $675M | N/A | — | — |
 Kaken Pharmaceutical Co., Ltd. KKPCF | $1.0B | 72.51x | +81.5% | $56.91 |
Industry Average 2 peers with valid PE | — | 39.96x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 5.56x | $1.26 | -15.3% | |
2024-12-31 FY2024 | 6.56x | $1.11 | +28.6% | |
2023-12-31 FY2023 | 5.11x | $1.29 | -24.0% | |
2022-12-31 FY2022 | 6.71x | $0.98 | -17.1% | |
2021-12-31 FY2021 | 8.10x | $0.74 | -63.1% | |
2020-12-31 FY2020 | 21.95x | $0.37 | +64.3% | |
2019-12-31 FY2019 | 13.36x | $0.65 | +1.0% | |
2018-12-31 FY2018 | 13.23x | $0.64 | -13.0% | |
2017-12-31 FY2017 | 15.20x | $0.53 | +31.8% | |
2016-12-31 FY2016 | 11.54x | $0.75 | +23.8% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for China Shineway Pharmaceutical Group Limited (CSWYF) measures how much investors pay for each dollar of the company's trailing earnings. CSWYF's current PE ratio of 5.72x is calculated by dividing its stock price of $1.08 by its TTM earnings per share of $1.26.
Frequently asked questions
CSWYF pe ratio · 6 questionsCSWYF's current PE ratio is 5.72x as of 2026-06-09, based on a stock price of $1.08 and TTM EPS of $1.26. Data sourced from Financial Modeling Prep via CSWYF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · China Shineway Pharmaceutical Group Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09